A POSTDOCTORAL POSITION is available at the Translational Cancer Medicine research group led by Academy professor Kari Alitalo, in the Faculty of Medicine in the University of Helsinki, Finland. The Alitalo group is located in Biomedicum Helsinki of the Academic Medical Center Helsinki (Meilahti campus), which ranks at the top 10 medical campuses in Europe and among the top 50 globally. Alitalo leads the Translational Cancer Medicine Program and the Wihuri Research Institute, which both provide a multidisciplinary research environment for basic and translational research with state-of-the-art facilities, cutting-edge technologies and synergistic expertise of several research groups.
The position is funded by the Theralymph Horizon 2020 program ”Gene Therapy to restore lymphatic flow lymphedema”. The Theralymph translational research program brings together scientists from six European countries, one Biotech company and the Toulouse Rangueil hospital in France. The main objective of Theralymph is to establish non-integrative gene therapy methods for growth of lymphatic vessels after their damage.
The main objectives are to 1) Describe the physiopathology related to loss of lymphatic vessels. 2) Identify therapeutic targets for restoration of functional lymphatic vessels. 3) Validate therapeutic targets in preclinical models of loss of lymphatic function. 4) Perform a Phase I/IIa clinical gene therapy trial in patients who developed lymphedema after breast cancer.
The candidate will validate therapeutic targets and tools in vivo in mouse models of altered lymphatic vessel function.
We are looking for a highly motivated postdoctoral research scientist with a strong enthusiasm towards science. A successful candidate should have a PhD degree and strong background in molecular and cell biology, cellular biochemistry, genetics, or other related discipline. Previous experience with biomedical and/or lymphedema research are considered an advantage and expertise in bioinformatics and mouse models is beneficial. Excellent communication skills (in English), and technical and organizational abilities are expected.
Research in the laboratory led by Academy Professor Kari Alitalo focuses on Vascular biology related to human diseases, discovery of new disease-related functions of vascular endothelial growth factors, angiopoietins, angiogenesis and lymphangiogenesis. The goal is to use this knowledge for establishment of preclinical models for more effective targeted therapies on these diseases.
The position is available as soon as the best applicant is available. The project allows a two-year fixed-term position, with a possibility of extension. A trial period of six months will be applied.
The initial starting salary is at the level 5 for teaching and research personnel according to the salary system of the Finnish universities. In addition, a salary component will be paid based on personal performance, with an overall starting salary to approximately 3200 EUR per month, which is increased based on the qualifications and previous relevant research experience of the candidate.
Please submit your application via the University of Helsinki Recruitment System by clicking the ‘Apply for the position' button below. Internal applicants (i.e. current employees of the University of Helsinki) should submit their applications through the SAP HR portal. If you need support with the recruitment system, please contact recruitment (at) helsinki.fi.
Please attach the following documents to your application as a single PDF file:
• Cover letter (maximum 1 page) that details your past experience and motivation for applying to the post.
• CV (including publications)
• Contact details of at least two referees
The deadline for applications is May 16th 2021. Interviews will be conducted either in person or online.
For more information on the position, please contact Academy professor Kari Alitalo, kari.alitalo (at ) helsinki.fi. For additional information on the recruitment process, you may also contact HR Specialist Päivi Sinisalo, paivi.sinisalo (at) helsinki.fi.
About the University of Helsinki
The University of Helsinki (UH), founded in 1640, is a vibrant scientific community of 40,000 students and researchers. It is one of the leading multidisciplinary research universities and ranks among the top 100 international universities in the world. It is currently investing heavily in life sciences research. UH offers comprehensive services to its employees, including occupational health care and health insurance, sports facilities, and opportunities for professional development.
Together with the Helsinki University Hospital (HUS) and the Helsinki Institute of Life Sciences (HiLIFE), the Faculty of Medicine, University of Helsinki, constitutes the Academic Medical Center Helsinki (AMCH). This medical center has been very successful in international comparisons, ranking among the top 10 medical campuses in Europe and among the top 50 globally.
16.05.2021 23:59 EEST